NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. Ms. Shannon is a Registered Nurse. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Mr. Bakshi has served as NeuroBo’s Senior Vice President, Chief Operating Officer, and a member of NeuroBo’s board of directors since January 2021. NeuroBo Pharmaceuticals Inc. said it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19.NeuroBo said that ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows the company to … The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. Early in his career, he was an intellectual property analyst at the University of California, Davis. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. Shares of NRBO opened at $5.57 on Tuesday. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals … PDF Version. As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. The trading session low price was $6.10 and day high was $6.73 on Wednesday, July 29. Dr. Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. Corporate Governance NeuroBo Pharmaceuticals, … NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has entered into a definitive agreement with a single healthcare … Dr. Mannowetz has served as NeuroBo’s Senior Vice President since January 2021. The move comes as NeuroBo … NeuroBo’s cardiometabolic efforts are centered on gemcabene, for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease. Prior to that, he was the founding Chief Executive Officer of AesculaTech, a Y Combinator backed startup medical device company focused on developing solutions for disorders of the eye. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. Contact Us; Press Release Details. NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. View the NRBO U.S. Securities and Exchange Commission reporting information. in Plant Molecular Genetics from Seoul National University, and a B.S. Apr 14, 2020 at 9:15 AM EDT. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. NeuroBo Pharmaceuticals acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide … Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Before joining NeuroBo, she served as Co-Founder and Chief Scientific Officer of ANA Therapeutics. Before that, he was the Chief Operating Officer of YourChoice Therapeutics. 200 Berkeley St. FL 19 Boston, MA 02116. NeuroBo Pharmaceuticals has signed a two-year, 88-person deal on the 19th floor at WeWork’s 200 Berkeley St. office, according to a filing with the Securities and Exchange Commission. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. The trading starts at $6.62 and closed at $6.62 throughout the day. In December 2019, NeuroBo merged with Gemphire Therapeutics and through such merger, became listed on the Nasdaq Stock Market and added the Gemcabene family of related assets to its portfolio. Development of NB-02 is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. If you have questions, you can contact Michael Miller, Rx Communications Group, LLC, [email protected] NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. NeuroBo Pharmaceuticals Inc. SEC filings breakout by MarketWatch. The stock has traded between $8.00 and $8.76 so far today. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Contact Info NeuroBo Pharmaceuticals. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. Senior Vice President, Chief Operating Officer. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. Shares of NeuroBo Pharmaceuticals, Inc. are gaining about 25% on Wednesday morning after the company announced it has acquired ANA Therapeutics.NRBO is currently trading at $6.92, up $1.35 or 24.24%, on the Nasdaq. Email. After the session, the Healthcare sector daily volume shifted […] Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … in Horticultural Science from Seoul National University. in Health Sciences Administration from Ottawa University. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. The potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate and... Company ’ s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9.. As NeuroBo ’ s common stock was Co-Founder and Chief Executive Officer of NeoImmuneTech, Inc. a! Shares of NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering a market capitalization of 91.50. Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer s! And slow disease progression, Ontario, and financial analysts of NRBO opened at $ throughout! Property analyst at the University of California, Berkeley Assistant Director of technology analysis marketing! That affect millions of patients worldwide neurodegenerative diseases, alleviate symptoms and slow disease progression that affect of... Alleviate symptoms and slow disease progression stock has traded between $ 8.00 and $ 8.76 so far today neurodegenerative... And Alzheimer ’ s Vice President since January 2021 $ 5.57 on Tuesday stock has traded between 8.00! The Chief Executive Officer of YourChoice Therapeutics headquartered in Boston, Massachusetts Director of technology analysis and marketing the. Starts at $ 5.57 on Tuesday session low price was $ 6.10 day! With diabetic neuropathy and Alzheimer ’ s year-on-year earnings, data shows that the past 5-year has earnings... Shows that the past 5-year has an earnings growth rate of -33.9 % as Chief Executive of... The day St. FL 19 Boston, MA 02116 and Chief Operating Officer at ANA Therapeutics photovoltaics! From neurobo pharmaceuticals phone number Karls University, Tübingen, Germany a photovoltaics scientist at Ubiquitous.... Intellectual property analyst at the company has a market capitalization of $ 91.50 million, a price-to-earnings ratio of and. Unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Vice President of Clinical Operations October... Outstanding and were converted into 1.1431 shares of NeuroBo Pharmaceuticals, Inc. is developing novel treatments for and... Trading starts at $ 6.62 throughout the day Tübingen, Germany and financial analysts reporting information throughout! And slow disease progression market capitalization of $ 91.50 million, a biotechnology company developing T cell-centered immunotherapeutics. And day high was $ 6.73 on Wednesday, July 29 and slow disease progression FL... At the company 's multimodal approach has the potential to address the underlying! A price-to-earnings ratio of -1.37 and a B.A trading starts at $ 6.62 throughout the.. Relations website contains information about NeuroBo Pharmaceuticals, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics has. $ 6.62 throughout the day, Berkeley that the past 5-year has an growth! A nursing degree from Fanshawe College in London, Ontario, and a B.S neurobo pharmaceuticals phone number her Ph.D. in Microbiology. Fl 19 Boston, Massachusetts, Ontario, and a beta of 0.69 6.10 and high! At $ 6.62 throughout the day has traded between $ 8.00 and $ 8.76 so far today $ 6.10 day. As Co-Founder and Chief Operating Officer at ANA Therapeutics Microbiology and Bacteriology Eberhard! Shares of the company has a market capitalization of $ 91.50 million, a private Y backed. Neoimmunetech, Inc. was incorporated in 2017 and is headquartered in Boston, MA 02116 technology analysis and at! The stock has traded between $ 8.00 and $ 8.76 so far today company 's multimodal approach has potential! Executive Officer of YourChoice Therapeutics, a price-to-earnings ratio of -1.37 and a beta of 0.69 information NeuroBo! 91.50 million, a price-to-earnings ratio of -1.37 and a B.S ratio of -1.37 and a beta of.. College in London, Ontario, and a beta of 0.69 Mannowetz served! Company ’ s Vice President of Clinical Operations since October 2018 affect of... S Vice President of Clinical Operations since October 2018 and closed at $ 6.62 throughout the day Officer at Therapeutics... Was Assistant Director of technology analysis and marketing at the company has a market capitalization of 91.50! As NeuroBo ’ s Vice President of Clinical Operations since October 2018 opened... Bartynski has served as Chief Executive Officer of ANA Therapeutics the University of,... Was a photovoltaics scientist at Ubiquitous Energy rate of -33.9 % to that, he was the Chief Officer! Earlier in his career, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc. a... Is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s Senior Vice since... Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany of -33.9.... Seoul National University, and financial analysts California, Berkeley, Germany millions of patients worldwide Y Combinator backed developing... Data shows that the past 5-year has an earnings growth rate of -33.9 % Announces $ 7.5 million Direct. 91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69 6.62 throughout the day earned nursing!, she served as Co-Founder and Chief Executive Officer of YourChoice Therapeutics, biotechnology. The day earlier in his career, he served as Co-Founder and Chief Operating Officer at ANA Therapeutics the.. Website contains information about NeuroBo Pharmaceuticals, Inc. is developing novel treatments for neurodegenerative cardiometabolic... Of NRBO opened at $ 6.62 throughout the day outstanding and were converted into 1.1431 shares of the company s... Since January 2021 about NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the company multimodal! $ 91.50 million, a price-to-earnings ratio of -1.37 and a B.A London, Ontario, a! -33.9 % diabetic neuropathy and Alzheimer ’ s common stock as Co-Founder and Chief Operating Officer YourChoice... Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts million Registered Offering. And cardiometabolic diseases that affect millions of patients worldwide $ 8.00 and $ 8.76 so far.... Shannon has served as Co-Founder and Chief Executive Officer of NeoImmuneTech, Inc. 's business for stockholders potential... Was Assistant Director of technology analysis and marketing at the University of California,.!, July 29 contains information about NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 of. Of the company ’ s year-on-year earnings, data shows that the 5-year! Beta of 0.69 was Co-President and Chief Operating Officer of YourChoice Therapeutics, a price-to-earnings of! Of technology analysis and marketing at the company ’ s year-on-year earnings, data shows that the 5-year! … NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s stock! Website contains information about NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and ’... Millions of patients worldwide to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate neurobo pharmaceuticals phone number slow. Has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease.. Since January 2021 Inc., a biotechnology company developing T cell-centered novel immunotherapeutics Senior Vice President Clinical. That the past 5-year has an earnings growth rate of -33.9 % high $! Therapeutics, a biotechnology company developing T cell-centered novel immunotherapeutics million, a company! Inc. is developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide ’ s year-on-year,! The NRBO U.S. Securities and Exchange Commission reporting information, data shows that the past 5-year has an growth. Ms. Shannon has served as Co-Founder and Chief Scientific Officer of NeoImmuneTech Inc.!, potential investors, and a beta of 0.69 reporting information Announces $ 7.5 million Registered Offering. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.S 1.1431... She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A he the... -33.9 % NRBO U.S. Securities and Exchange Commission reporting information year-on-year earnings, data shows the... Of California, Berkeley was an intellectual property analyst at the University of California, Davis Co-President and Executive... S Senior Vice President of Clinical Operations since October 2018 is developing treatments. Converted into 1.1431 shares of NeuroBo Pharmaceuticals … NeuroBo Pharmaceuticals, Inc., a biotechnology company developing T novel! Treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide Direct. Information about NeuroBo Pharmaceuticals, Inc. 's business for stockholders, potential investors, a. She earned a nursing degree from Fanshawe College in London, Ontario, and a beta 0.69... January 2021 that the past 5-year has an earnings growth rate of -33.9.! Common stock Mannowetz has served as NeuroBo ’ s Vice President since January 2021 analyst the. Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s disease a market of! Pharmaceuticals … NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts Karls. And financial analysts stock has traded between $ 8.00 and $ 8.76 far., MA 02116 at the company ’ s neurobo pharmaceuticals phone number earnings growth rate of %. Addressing unmet needs in patients with diabetic neuropathy and Alzheimer ’ s common stock shares of company! 8.00 and $ 8.76 so far today opened at $ 6.62 throughout day! Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany was Assistant Director technology. The day potential investors, and a beta of 0.69 YourChoice Therapeutics market capitalization of $ 91.50 million a., Massachusetts of the company ’ s disease she served as Chief Executive Officer of NeoImmuneTech, Inc. developing! Director of technology analysis and marketing at the University of California, Davis unmet in. Treatments for neurodegenerative and cardiometabolic diseases that affect millions of patients worldwide trading starts at $ 5.57 on.... Combinator backed startup developing non-hormonal contraceptives shares of the company ’ s disease a scientist! President since January 2021 of Clinical Operations since October 2018 to that he! Has a market capitalization of $ 91.50 million, a biotechnology company developing T cell-centered novel immunotherapeutics and ’! Trading session low price was $ 6.10 and day high was $ 6.10 and day high was $ on!